A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Targeted drug delivery systems improve anti-cancer efficacy by concentrating cytotoxic drugs within tumors, minimizing systemic toxicity.
• Natural ligands like folic acid, overexpressed on tumor cells, can be utilized as targeting moieties to enhance drug accumulation in tumors.
• Liposome encapsulation is a key strategy for delivering chemotherapeutic agents.

Purpose of the Study:

• To explore the potential of folic acid as a targeting ligand for liposome-based drug delivery systems.
• To evaluate the efficacy of folate-tagged poloxamer-coated liposomes (FDL) for targeted delivery of doxorubicin to tumors.
• To assess the anti-tumor activity and tumor-targeting capabilities of FDL in preclinical models.

Main Methods:

• Folic acid was incorporated into liposomes using folic acid-modified cholesterol (CPF).
• Folate-tagged poloxamer-coated liposomes (FDL) and conventional liposomes (DL) were prepared and characterized.
• Cellular uptake was assessed using fluorometric analysis in B16F10 melanoma cells.
• Biodistribution studies of radiolabeled liposomes were conducted.
• Anti-tumor activity was evaluated in murine B16F10 melanoma tumor-bearing mice.

Main Results:

• Folate-tagged poloxamer-coated liposomes (FDL) demonstrated significantly higher cellular uptake compared to conventional liposomes (DL).
• Biodistribution studies revealed significantly higher tumor accumulation of FDL versus DL.
• FDL exhibited superior inhibition of tumor growth in a murine melanoma model compared to DL.

Conclusions:

• Folate conjugation to liposomes enhances selective tumor targeting and drug delivery.
• The folate-conjugated nanoliposomal system shows significant potential for improving anti-tumor efficacy.
• This approach offers a promising strategy for reducing systemic toxicity in cancer chemotherapy.